ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Avita Medical Inc

Avita Medical Inc (RCEL)

11.77
0.29
(2.53%)
Cerrado 21 Diciembre 3:00PM
11.77
-0.014
(-0.12%)
Fuera de horario: 4:43PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
11.77
Postura de Compra
11.03
Postura de Venta
12.46
Volume Operado de la Acción
154,223
11.45 Rango del Día 12.1399
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
11.48
Precio de Apertura
11.45
Última hora de negociación
Volumen financiero
US$ 1,788,394
Precio Promedio Ponderado
11.5962
Volumen promedio (3 m)
-
Acciones en circulación
26,217,629
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-8.73
Beneficio por acción (BPA)
-1.35
turnover
51.57M
Beneficio neto
-35.38M

Acerca de Avita Medical Inc

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinic... Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Mostrar más

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sede
Wilmington, Delaware, USA
Fundado
-
Avita Medical Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker RCEL. The last closing price for Avita Medical was US$11.48. Over the last year, Avita Medical shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Avita Medical currently has 26,217,629 shares in issue. The market capitalisation of Avita Medical is US$300.98 million. Avita Medical has a price to earnings ratio (PE ratio) of -8.73.

RCEL Últimas noticias

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDermCohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif...

AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand

VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for...

AVITA Medical to Host Investor Webinar Briefing

VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

AVITA Medical Reports Third Quarter Financial Results

VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

AVITA Medical to Announce Third Quarter 2024 Financial Results

VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

AVITA Medical to Present at 2024 Cantor Global Healthcare Conference

VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference

VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

RCEL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Avita Medical?
El precio actual de las acciones de Avita Medical es US$ 11.77
¿Cuántas acciones de Avita Medical están en circulación?
Avita Medical tiene 26,217,629 acciones en circulación
¿Cuál es la capitalización de mercado de Avita Medical?
La capitalización de mercado de Avita Medical es USD 300.98M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Avita Medical?
Avita Medical ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Avita Medical?
El ratio precio/beneficio de Avita Medical es -8.73
¿Cuál es el ratio de efectivo a ventas de Avita Medical?
El ratio de efectivo a ventas de Avita Medical es 5.99
¿Cuál es la moneda de reporte de Avita Medical?
Avita Medical presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Avita Medical?
El último ingresos anual de Avita Medical es USD 51.57M
¿Cuál es el último beneficio anual de Avita Medical?
El último beneficio anual de Avita Medical es USD -35.38M
¿Cuál es la dirección registrada de Avita Medical?
La dirección registrada de Avita Medical es 3411 SILVERSIDE ROAD TATNALL BUILDING, SUITE 104, NEW CASTLE, WILMINGTON, DELAWARE, 19810
¿Cuál es la dirección del sitio web de Avita Medical?
La dirección del sitio web de Avita Medical es www.avitamedical.com
¿En qué sector industrial opera Avita Medical?
Avita Medical opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

RCEL Discussion

Ver más
pick pick 3 meses hace
This happened in my backyard. I live near Powhatan and read of the fire. (There are a lot of horse farms around here; Powhatan and Chesterfield counties, where I live are suburds of Richmond, where VCU is located. VCU Hospital was formerly known as the Medical College of Virginia)

It's good PR for Avita, and the widespread used of Recell. 
👍️0
Fmello Fmello 4 meses hace
Medical director uses new technology to save horse’s skin after massive barn fire

https://www.12onyourside.com/2024/08/02/medical-director-uses-new-technology-save-horses-skin-after-massive-barn-fire/
👍️0
Spetch Spetch 5 meses hace
Hi guys, what the hell just happened? We come out with a new product and it drops 10%.
👍️0
Spetch Spetch 5 meses hace
Come on bod
Let’s see you put some money where your mouth is As this long-term drop is ridiculous
👍️0
Dretired Dretired 6 meses hace
These individual news story need to be developed in all the metropolitan areas throughout the country.
👍️0
Dretired Dretired 6 meses hace
Yes good reference post.
👍️0
Spetch Spetch 6 meses hace
Hi guys
Would be nice to see some of the board put some money into this would show confidence in the new product
What are your thoughts?
👍️0
Monksdream Monksdream 6 meses hace
RCEL under $10
👍️0
Cake10 Cake10 7 meses hace
RECELL Go Gets FDA Approval

Massive!!

THIS IS THE WAY.

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-announces-fda-approval-recell-go
👍️0
believeinsteven believeinsteven 7 meses hace
Morningstar: Avita Medical Shares Remain Undervalued, With Long-Term Opportunity Intact
👍️ 1
Trueheart Trueheart 7 meses hace
Gratifying? It's my best guess that you're the type that drives by horrible traffic accidents, slowing down to view the carnage, the blood and mangled bodies, just so's you can have something to say that will distract your wife from her crossword puzzle as you're eating dinner.
Be a mensch!

Trueheart
👍️0
Spetch Spetch 8 meses hace
Hi all
Would be nice to see the directors making some share buys at these low prices to show confidence in the future
👍️0
Fmello Fmello 8 meses hace
https://www.ktnv.com/news/unique-burn-treatment-helps-logandale-girl-recover-nearly-scar-free-at-las-vegas-hospital
👍️0
Monksdream Monksdream 9 meses hace
RCEL over $10
👍️0
Cake10 Cake10 10 meses hace
As I stated, how he opines is immaterial (despite the fact that he’s on record for liking the company, which is why he had Perry on twice and talked about liking the product many times thereafter). But that was a long time ago. Though positive sentiment never hurts, his “OPINEion” is largely immaterial in the scheme of the facts: FDA approvals, broadening scope, increasing sales, plenty of cash, halo product, and a path to profitability, to mention a few.

And, yes, he does do quite intensive research. He may be wacky, but he’s extremely thorough and highly intelligent. Both he and CNBC have extensive resources and staff that do serious due diligence. I assure you he will see what we ALL see. And he will like A LOT. Maybe all of it. But yes, in the final analysis, he may hedge because of the market cap. Or because they’re not yet profitable though that’s not an intransigent sentiment with him. He mainly holds that position in a risk-off environment with recessionary risk or looming rate hikes as we’ve been in the last couple years.

But these days are different. Have you seen Bitcoin lately? Upcoming IPOs? Anticipated rate cuts? We’re in a very different market than a few months ago and he may change his tune, especially when this company will be profitable by next year. Or he may not. Doesn’t really matter.

No — this is ALL about visibility. Institutions are very well aware of this stock with a couple having taken deep bites, but the retail investor by and a large? I don’t know. This stock is/was mostly held by retail last I checked, but that doesn’t necessarily indicate plurality. Many may have it off their radars these days. Many may just need a couple of positive comments that piques their interest and jives with their risk tolerance. This is who I would expect to come looking. Thousands will look. Some will buy. Maybe small fish. Maybe big fish. There’s no way to know. All I’m saying is “hold on tight.” TiGETTY-tight.

PS: relying “on the new executives executing what seems like a very workable strategy” is in no way shape or form mutually exclusive to gaining massive visibility. Both can be had.
👍️0
MONYMAN3 MONYMAN3 10 meses hace
I'm afraid he may not opine positively. You know he doesn't recommend stocks that aren't making money? Also, as you say, market cap may not be big enough. If he really did intensive research, I believe he would come out with a positive recommendation. If anything, that would give us a short term pop. Better to rely on the new executives executing what seems like a very workable strategy.
👍️0
Cake10 Cake10 10 meses hace
Mad Money episode tonight 2/29/24 … on Leap Day of all days.

Caller: Cramer what do you think about Avita Medical?

Cramer: I do not know this company! I will have to do some work.

First of all, the question surprised me. Second, I was surprised they allowed the call to go through as the show, I believe, requires a company to have a minimum market cap of $1B or $1.5B for it to be discussed. He had Mike Perry ON his show twice (once in person) around 2019 or 2020 during its huge run up toward all-time highs when it was around that market cap. He will definitely remember once his staff does their due diligence. This is a FAR more advanced company than it was then.

Usually (maybe always) he’ll do a follow-up with his “homework” updating viewers on questions about stocks on which he was stumped by callers.

This should be VERY interesting, not necessarily because of what he does/doesn’t have to say (you should rely on your own research), but for the mere fact that he has a massive audience and massive platform for visibility.

Hold on VERY tightly to your shares until if/that segment airs, potentially within the next few weeks.
👍️ 1
artfulife artfulife 10 meses hace
Feb 29 (Reuters) - AVITA Medical Inc(RCEL):

* AVITA MEDICAL SUBMITS RESPONSE TO FDA, RESUMING REVIEW CLOCK FOR RECELL GO PMA SUPPLEMENT

* AVITA MEDICAL INC(RCEL) - EXPECT FDA APPROVAL ON MAY 30, 2024, POSITIONING US FOR A PRODUCT LAUNCH ON MAY 31, 2024

Yes!
👍️0
MONYMAN3 MONYMAN3 10 meses hace
https://ir.enovix.com/events/event-details/journey-scale-podcast-feb-2024-fab2-updates-coo-ajay-marathe
👍️0
MONYMAN3 MONYMAN3 11 meses hace
https://seekingalpha.com/news/4056668-cantor-picks-rcel-as-best-2024-medtech-idea-bullish-on-pacb-axgn-cers
👍️0
Fmello Fmello 11 meses hace
👍️ 2
Fmello Fmello 11 meses hace
The Aussie stock closed up 12.59% tonight.
👍️0
Fmello Fmello 11 meses hace
https://www-presseportal-de.translate.goog/pm/167421/5687690?_x_tr_sl=de&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc

PMI CEO Christian Planck: "We are very pleased that we can now offer RECELL ® in Germany, Austria and Switzerland. Our customers have been asking about this technology for years. In fact, it is a perfect addition to our own portfolio the one- stop shop technology."

"Our partnership with PolyMedics Innovations is the first step in our strategic global expansion," said Jim Corbett, Chief Executive Officer of AVITA Medical. "PMI's proven track record and expertise in the global distribution of innovative wound treatments make them an ideal partner. We look forward to a successful collaboration that will enable us to reach more patients worldwide."
👍️0
MONYMAN3 MONYMAN3 1 año hace
https://us02web.zoom.us/rec/play/D_NT2rl2dZcpc7L_XUt6VJh81E_HIM21mngBXR6KjZHRPs0VCBfzNWiyCOb7vHVaubUpQSvF7WhSZaPB.oSXXXZT66WOzvHuC?hasValidToken=false&canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Fus02web.zoom.us%2Frec%2Fshare%2FDh9UFDWQhFjYF0S9afouXwsCKphzVngmXyS6lDfdDuXYk52XXdCrVctLIq0WiYkA.PO58b8CAaqc_JBTL RCEL Investor Webinar
👍️0
Fmello Fmello 1 año hace
Here's a detailed presentation about Recell.
(warning: some of the pics are very graphic)

https://avitamedical.showpad.com/share/NAPlEVouN92Enz79yKX4z
👍️0
believeinsteven believeinsteven 1 año hace
“We have achieved significant commercial revenue growth rates for
the last three quarters of 40%, 42% and 51%, respectively, over the
same periods in the previous year,” said David O’Toole, Chief
Financial Officer of AVITA Medical. “Further, we remain confident
that our cash reserves position us to achieve our goals and reach
profitability in 2025.”
👍️0
Spetch Spetch 1 año hace
Hi
Not the worst results ever moving forward
👍️0
artfulife artfulife 1 año hace
He's just making the rounds with another "told you so" post. 🎱🦨 😄
👍️0
Windbag1014 Windbag1014 1 año hace
You're back.
Pull all the wings off the flies? Lots of legless grasshoppers in your neighborhood. No dead people to pick on? Oh the gratification.
👍️0
bar1080 bar1080 1 año hace
Gratifying watching much "Perpetual Startup" crap collapsing. Thinking of Plug Power, LWLG (Lightwave Logic), SolarWindow, Liquidmetal.... and maybe several hundred more. This market rewards large caps with audited profits and regular cash dividends. Bad news for IHUB and its dead stock boards and company insiders drawing monstrously large wages for running itty bitty penny stocks where success is always "just around the corner."

Also: "Wow, I see this board is >ten years old. I don't buy tiny biomed stocks. Most are perpetual startups. Vapor. I require GAAP profits and usually dividends.
But I make money with my investments." https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171926857
👍️0
Spetch Spetch 1 año hace
Why the total free fall of share price
Any comments
Thanks steve
👍️0
Align Align 1 año hace
Apologies, it looks like I was wrong about preliminary results.
👍️0
Align Align 1 año hace
After listening to what the CEO had to say about sales momentum during two conferences in September, preliminary results and revenue guidance upgrades are possible this week in my view.

The next scheduled event after that is the earnings call and investor briefing in November where they’ll be providing earnings results, strategies on future expansions and hopefully additional commentary on the revised expectations on Recell Go approval.
👍️0
Spetch Spetch 1 año hace
Hi
Any idea next event that could turn share price around
Fall was to much for what is short delay in terms of things
👍️0
Fmello Fmello 1 año hace
That drop seems pretty excessive.
👍️0
Spetch Spetch 1 año hace
So over reaction by market
👍️0
Windbag1014 Windbag1014 1 año hace
As previously disclosed, on June 30, 2023, AVITA Medical, Inc. (the
“Company”) submitted a premarket approval supplement application
(the “PMA”) to the U.S. Food and Drug Administration (the “FDA”)
for its latest device, RECELL GO™. The submission initiated a
prioritized, interactive review of the PMA under the FDA’s
Breakthrough Device program, which follows a 180-day review
cycle.


At the halfway point of the process, the Company received notice
from the FDA that additional information regarding the PMA is
required for the continuation of a substantive review. This
request, which is not unique to the Breakthrough Device Program,
places the application file on hold for approximately 4 to 6 months
while the Company addresses the FDA's questions. Upon the Company’s
submission of a complete response to the FDA’s request, the
application will reenter the 180-day cycle, with 90 days remaining
in the review period. This timing would imply a product launch
between May 1 and July 1, 2024.
👍️0
Spetch Spetch 1 año hace
I’m in the UK, so don’t quite understand what this form relates to
👍️0
Spetch Spetch 1 año hace
Hi chaps, can anyone explain why 20% down thank you
👍️0
Windbag1014 Windbag1014 1 año hace
https://ih.advfn.com/stock-market/NASDAQ/avita-medical-RCEL/stock-news/92172037/form-8-k-current-report
👍️0
believeinsteven believeinsteven 1 año hace
What did I miss? Why the drop in share price?
👍️0
MONYMAN3 MONYMAN3 1 año hace
https://us02web.zoom.us/rec/play/8LuDNA4gvw9rySzh-Jq5hf2dN49r88m2nCZKTtexSjouqZawLCRgGbt1nh2P-tNaDJ8j8tVxOnNrHuwr.3HIH8zEi2s3oRXPY?hasValidToken=false&canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Fus02web.zoom.us%2Frec%2Fshare%2FgCZkGrUNe9KDQBYnXVInZRNMQ_onwfkLvCsWsFWLIoqOGkGOd6_pmcEGuJ6Lm-t4.fzvS7nm7wh5uvXdd They seem on track with the new sales personnel. I'm looking for a pretty good bump in revenues this next quarter as the new sales team pick the low hanging fruit from the hospitals that we are already in for burns. Soft tissue wounds should be a no brainer for them.
👍️0
Fmello Fmello 1 año hace
Here are some screenshots of the slides from today's webinar:



















👍️ 1
Fmello Fmello 1 año hace
Avita donated Recell kits to Hawaiian burn centers to treat victims of that big wildfire.
👍️0
Fmello Fmello 1 año hace
The webinar just started.
👍️0
Fmello Fmello 1 año hace
AVITA Medical - Investor Webinar Briefing
Date & Time: Aug 15, 2023 06:00 PM central time

https://us02web.zoom.us/webinar/register/WN_QYXQA5P-TsGjPVD01tULxw#/registration
👍️0
Noseyrosey Noseyrosey 1 año hace
I agree
👍️0
MONYMAN3 MONYMAN3 1 año hace
I don't mind the higher expense since I view it as an investment in the future. Sales people can reach the 20+ kit sales in as little as 3-4 months. This ramp should really ramp once we get the automated system out in the field. That RCEL GO system greatly expands the target customers from mainly hospitals down to the clinic level.
👍️0
Fmello Fmello 1 año hace
I wonder if BARDA's Recell stockpile will be used to treat burn victims from the Hawaiian wildfires?
👍️0
Spetch Spetch 1 año hace
Pos could have better loss per share though
👍️0

Su Consulta Reciente

Delayed Upgrade Clock